{
  "id": 12138872,
  "title": "Epicrispr builds case for FSHD treatment with updated data for EPI-321",
  "url": "https://urgent.news/2026/10/05/epicrispr-builds-case-for-fshd-treatment-with-updated-data-for-epi-321",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-05T11:00:22.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/epicrispr-builds-case-for-fshd-treatment-with-updated-data-for-epi-321/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy. Twelve people have been dosed with the therapy, EPI-321, as part of the ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}